Skip to main content

Table 4 Comparison of SLEDAI between the two groups

From: The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study

Indicator

Cancer group (n = 51) (positive/total, percentage)

Control group (n = 204) (positive/total, percentage)

P value

Low C3

16/36, 44.44%

74/90, 82.22%

< 0.01

Low C4

14/36, 38.89%

48/90, 53.33%

0.17

Low WBC

6/48, 12.50%

26/102, 25.49%

0.09

Low PLT

10/48, 20.83%

34/102, 33.33%

0.13

Proteinuria

6/49, 12.24%

36/100, 36.00%

< 0.01

SLEDAI, median

2

8

< 0.01

  1. WBC white blood cell, PLT platelet, SLEDAI SLE Disease Activity Index